Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical, Inc. (ISRG) is a medical technology company headquartered in Sunnyvale, California and known for its role in minimally invasive care and robotic-assisted surgery. Its news flow frequently centers on developments related to the da Vinci surgical systems and the Ion endoluminal system, along with financial performance updates and regulatory milestones.
Investors and healthcare professionals following ISRG news can expect regular earnings announcements, where the company reports quarterly and preliminary annual financial results. These updates typically highlight worldwide procedure growth on da Vinci and Ion platforms, changes in the installed base of systems, and trends in systems, instruments, and accessories revenue.
Another major category of Intuitive news involves product clearances and platform enhancements. Recent press releases describe FDA clearances expanding indications for the da Vinci Single Port (SP) system to additional general surgery procedures, clearance of advanced energy instruments such as Vessel Sealer Curved, and regulatory certifications for the da Vinci 5 system in regions including the European Union and Japan. News also covers software and digital features for da Vinci 5, such as Force Gauge, In-Console Video Replay, and Network CCM for remote software updates.
Intuitive’s news feed also includes updates on the Ion endoluminal system, including FDA-cleared software releases that introduce artificial intelligence across Ion’s navigational workflow and integrate advanced imaging capabilities to support lung biopsy procedures. Additional stories describe demonstrations of telesurgery capabilities using da Vinci 5 and collaborations with hospitals adopting newer platforms.
For those tracking ISRG, this news page provides a consolidated view of company press releases, allowing readers to monitor procedure and system trends, regulatory progress, and technology updates that shape Intuitive’s position in robotic-assisted surgery and minimally invasive care.
Intuitive (Nasdaq: ISRG) reported Q3 2021 financial results, highlighting a 30% increase in revenue to $1.40 billion compared to Q3 2020. The number of da Vinci systems shipped rose 72% to 336, and the total installed base increased to 6,525 systems. Net income reached $381 million ($1.04 per diluted share), up from $314 million in the same quarter last year. The company's cash and investments totaled $8.2 billion, indicating strong operational cash generation.
Intuitive announced preliminary data from the PRECIsE trial, a post-market evaluation of its Ion endoluminal system, at the CHEST conference. The system achieved an 83% diagnostic yield for pulmonary nodule biopsies across 69 subjects, with 82% for nodules 1-2 cm and 85% for 2-3 cm. The Ion system reported no serious adverse events and a sensitivity for malignancy ranging from 84% to 88%. This trial involves a total of 365 patients, beginning enrollment in March 2019. Currently, over 70 Ion systems are installed in U.S. hospitals.
Intuitive (Nasdaq: ISRG) announces the appointment of Yong-Bum Choi as the new General Manager for South Korea, tasked with enhancing business strategy and operations in a key market for minimally invasive care. Choi brings over 26 years of healthcare experience from companies like Janssen and Eli Lilly, strengthening Intuitive's leadership in robotic-assisted surgery. Since entering South Korea in 2005, Intuitive has installed over 110 systems and facilitated more than 190,000 surgeries, positioning it for further growth under Choi's guidance.
Intuitive (Nasdaq: ISRG) announced a proposed three-for-one stock split pending shareholder approval. The Amendment to the Company’s Certificate of Incorporation is set for a vote at the Special Meeting on September 20, 2021. If approved, stockholders of record on September 27, 2021 will receive two additional shares for every share held, with trading expected to start on a split-adjusted basis on October 5, 2021. This move aims to enhance liquidity and accessibility for investors.
Intuitive (Nasdaq: ISRG) reported strong financial results for Q2 2021, with revenues of $1.46 billion, up 72% from $0.85 billion in Q2 2020. This growth is attributed to a 68% increase in da Vinci procedures and a significant rise in system shipments, totaling 328 units—an 84% increase year-over-year. GAAP net income reached $517 million, or $4.25 per diluted share, compared to $68 million a year earlier. The company ended the quarter with $7.7 billion in cash and investments, reflecting solid operational cash generation and recovery from pandemic-related disruptions.
Intuitive (Nasdaq: ISRG) announced the appointment of Dr. Monica P. Reed to its board of directors, effective April 22, 2021. Dr. Reed, a former executive at AdventHealth, has over 30 years of experience in healthcare leadership, including serving as chief medical officer and CEO at AdventHealth. Her extensive background in hospital administration is expected to enhance Intuitive's strategic direction in robotic-assisted surgery. CEO Gary Guthart expressed optimism about her contributions to improving service to surgeons and healthcare systems.
Intuitive (Nasdaq: ISRG) reported strong Q1 2021 results, with revenue reaching $1.29 billion, marking an 18% increase year-over-year. The company shipped 298 da Vinci Surgical Systems, a 26% rise from last year, and achieved an installed base of 6,142 systems, up 8%. GAAP net income also grew to $426 million ($3.51 per diluted share), compared to $314 million ($2.62 per diluted share) in Q1 2020. Instruments and accessories revenue rose 14% to $706 million, driven by a 16% increase in da Vinci procedure volume.
Intuitive (Nasdaq: ISRG) reported Q4 2020 revenue of $1.33 billion, up 4% year-over-year. The company experienced a 6% increase in da Vinci procedures but a 3% drop in system shipments, reflecting COVID-19 disruptions. GAAP net income rose to $365 million ($3.02 per diluted share), compared to $358 million ($2.99 per diluted share) in Q4 2019. Operating expenses included a $25 million contribution to the Intuitive Foundation. The installed base of da Vinci systems grew by 7% to 5,989 systems.
Intuitive (Nasdaq: ISRG) reported preliminary fourth quarter and full year 2020 financial results, revealing a 4% revenue increase to approximately $1.33 billion for Q4, while full year revenue declined 3% to about $4.36 billion. Worldwide da Vinci procedures rose by 6% in Q4 and 1% for the year, despite COVID-19 disruptions. However, surgical system shipments fell to 326 in Q4 2020 from 336 in 2019 and totaled 936 for the year, down from 1,119. Notably, instruments and accessories revenue grew by 11% in Q4, totaling approximately $747 million.
Intuitive Surgical (Nasdaq: ISRG) has launched Intuitive Ventures, a $100 million fund aimed at investing in minimally invasive care innovations. This fund will focus on early-stage companies in digital tools, precision diagnostics, and therapeutic technologies. Julian Nikolchev, President of Intuitive Ventures, emphasizes the goal to enhance the continuum of care. With a leadership team experienced in healthcare investment, Intuitive Ventures aims to leverage industry expertise to drive positive healthcare outcomes.
FAQ
What is the current stock price of Intuitive Surgical (ISRG)?
What is the market cap of Intuitive Surgical (ISRG)?
